CN109846882A - A kind of pharmaceutical composition and its application for analgesic - Google Patents
A kind of pharmaceutical composition and its application for analgesic Download PDFInfo
- Publication number
- CN109846882A CN109846882A CN201910169425.8A CN201910169425A CN109846882A CN 109846882 A CN109846882 A CN 109846882A CN 201910169425 A CN201910169425 A CN 201910169425A CN 109846882 A CN109846882 A CN 109846882A
- Authority
- CN
- China
- Prior art keywords
- pharmaceutical composition
- parts
- analgesic
- borneol
- drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention discloses a kind of pharmaceutical composition and its application for analgesic, the composition contains the drug of following parts by weight: 0.2-4 parts and borneol 200-1000 parts of buprenorphin hydrochloride.Borneol can help buprenorphin hydrochloride to be easier to promote concentration of the buprenorphin hydrochloride in blood brain by blood-brain barrier, increase its curative effect, while reducing buprenorphin hydrochloride in the accumulation of brain periphery, reduce the adverse reaction of buprenorphin hydrochloride, receive convenient for patient.The two generates synergistic effect in terms of analgesic, can reduce side reaction, and can absorb in sublingual administration.Pharmaceutical composition of the invention can be applied to the drug of preparation treatment of cancer pain.The pharmaceutical composition good effect, few side effects, at low cost, preparation method is simple, easy to industrialized production.
Description
Technical field
The invention belongs to pharmaceutical field, it is related to the pharmaceutical composition and its application for analgesic.
Background technique
Cancer pain is a common sympton of cancer, and the incidence in cancer patient is 24%~60%.Especially arrive
Cancer of late stage, the ratio of pain are more up to 75% or more.Pain is clinically divided into 10 grade 4 etc., 0 grade be it is painless, in 3 grades
Belong to mild pain, 4-6 grades belong to moderate pain, and 7 grades or more just belong to severe pain.Pain caused by cancer is but likely to be breached 10 grades.Institute
With many patients reach an advanced stage, and generate the thought committed suicide due to can't stand pain caused by cancer because bearing.The drug of pain relieving of cancers has very at present simultaneously
More side effects haves the shortcomings that effect is poor, dependence is strong, mainly based on injection, such as morphine, Sauteralgyl.Such analgesic
Agent has the serious side effect for inhibiting gastrointestinal motility, causes patient's disorders of digestion, malnutrition, resistance decline, into
One step aggravates having a delicate constitution for cancer patient.It there is no ideal oral, without injecting, not inhibiting gastrointestinal motility cancer at present
Anodyne.
Hydrochloric acid Lepetan lozenge be opiates maincenter analgesic drug product, intracerebral concentration more high effect is better, Lepetan with
Central nervous system u opiate receptor affinity is high, and has the central analgesic activity more longlasting compared with morphine, imitates for morphine analgesia
5-10 times or more of fruit, can direct oral cavity mucous membrane and respiratory mucosa directly absorb, route of administration is convenient and efficient.This passing medicine is only
For giving up opioid addiction, it not to be used for pain relieving of cancers.However, to still have analgesic time shorter for the drug, for
The severe pains such as pain caused by cancer need dosage larger, thus easily generate such as dizzy, drowsiness, vomiting serious side effects.
Therefore, be badly in need of at present a kind of Small side effects, analgesic time are long, can treat such as pain caused by cancer severe pain analgesic
Medicine.
Summary of the invention
It is an object of the present invention to provide a kind of pharmaceutical composition for capableing of effective severe pains such as treatment of cancer pain,
It is played and is acted synergistically by the combination of Chinese tradiational and Western medicine, multiple target point therapeutic intervention severe pain.
It is a further object to provide aforementioned pharmaceutical compositions answering in the drug of preparation treatment of cancer pain
With.
The purpose of the present invention is what is realized by following technical proposal:
A kind of pharmaceutical composition for analgesic, including hydrochloric acid buprenophine and borneol.
Preferably, described pharmaceutical composition includes the drug of following parts by weight: 0.2-4 parts of hydrochloric acid buprenophine and borneol
200-1000 parts.
It is highly preferred that described pharmaceutical composition includes the drug of following parts by weight: 0.4-3.0 parts of hydrochloric acid buprenophine and ice
300-800 parts of piece.
Most preferably, described pharmaceutical composition includes the drug of following parts by weight: 2 parts of hydrochloric acid buprenophine and borneol 500
Part.
The dosage form of described pharmaceutical composition can be any dosage form of pharmacy permission, preferably sublingual to contain agent, transdermal patch, piece
Agent, granule, pulvis, pill, oral solution, spray, film.
Application of the described pharmaceutical composition in the drug of preparation treatment of cancer pain.
Buprenorphin hydrochloride is central anodyne, and the medicine is better in the higher analgesic effect of content of intracerebral.
There is borneol fragrance to walk to alter, promoting qi circulation and relieving pain, Opening Blood Brain Barrier, the function of protecting central nervous system.The present invention
People is the study found that borneol can help buprenorphin hydrochloride to be easier to promote buprenorphin hydrochloride in blood brain by blood-brain barrier
Concentration, to increase its curative effect, while reducing buprenorphin hydrochloride in the accumulation of brain periphery, reduce buprenorphin hydrochloride not
Good reaction receives convenient for patient.The two can mutually act synergistically in terms of analgesic, extend analgesic time, reduce pain grade,
Reduce side reaction.And two medicines can be absorbed in sublingual administration, realize perfect combination.The present invention is verified by clinical application, is taken
Obtained ideal effect.
Specific embodiment
The present invention is described combined with specific embodiments below, it should be noted that these case study on implementation are merely to illustrate, this
Invention should not be construed as limiting the invention.
1mg is portion in following preparation example, and preparation process and the auxiliary material selection of various dosage forms are the prior art.
Embodiment 1
Hydrochloric acid buprenophine 0.2g and borneol 200g are taken, is added 1200g sodium carboxymethyl starch (CNS-Na), suitable water is mixed
It closes uniformly, tabletting obtains 1000 tablets.
Embodiment 2
Hydrochloric acid buprenophine 2g and borneol 500g are taken, is added 1200g sodium carboxymethyl starch (CNS-Na), suitable water mixing
Uniformly, tabletting, obtain 1000 tablets.
Embodiment 3
Hydrochloric acid buprenophine 4g and borneol 1000g are taken, 500g microcrystalline cellulose, 750g dextrin, suitable water mixing is added
Uniformly, softwood processed, extrusion spheronization hair granulation, obtains granule.
Clinical therapeutic efficacy
Treatment cancer pain patient totally 115, be randomly divided into three groups each 35, wherein take pethidine hydrochloride piece (Sauteralgyl,
100mg/ times) and buprenorphin hydrochloride sublingual tablet (2mg/ times) is as a control group, take the embodiment of the present invention 2 tablet (1/
It is secondary, 2mg containing buprenorphine, borneol 500mg) it is used as observation group.
Count each group the average analgesic duration (patient reported pain alleviates the time aggravated again to pain) and
The number of cases of side effect occurs, as a result such as following table.
As seen from the above table, the pharmaceutical composition comprising buprenorphine and borneol of the invention can significantly extend analgesic time about
2-3h, and greatly reduce the side effect being also easy to produce when buprenorphine is used alone.Also, patient reports using of the invention
Pharmaceutical composition Sauteralgyl is relatively used alone in terms of reducing pain grade and the effect of buprenorphin hydrochloride becomes apparent, and is worth
It must promote.
It should be understood by those ordinary skilled in the art that: the discussion of any of the above embodiment is exemplary only, not
It is intended to imply that the scope of the present disclosure is limited to these embodiments.The embodiment of the present invention is intended to cover fall into the width of appended claims
All such replacements within the scope of general, modifications and variations.Therefore, all within the spirits and principles of the present invention, done
Any omission, modification, equivalent replacement, improvement etc., should all be included in the protection scope of the present invention.
Claims (7)
1. a kind of pharmaceutical composition for analgesic, which is characterized in that described pharmaceutical composition includes following drug: hydrochloric acid fourth third
Nuo Fei and borneol.
2. pharmaceutical composition as described in claim 1, which is characterized in that described pharmaceutical composition includes the medicine of following parts by weight
Object: 0.2-4 parts and borneol 200-1000 parts of hydrochloric acid buprenophine.
3. pharmaceutical composition as described in claim 1, which is characterized in that described pharmaceutical composition includes the medicine of following parts by weight
Object: 0.4-3.0 parts and borneol 300-800 parts of hydrochloric acid buprenophine.
4. pharmaceutical composition as described in claim 1, which is characterized in that described pharmaceutical composition includes the medicine of following parts by weight
Object: 2 parts and 500 parts of borneol of hydrochloric acid buprenophine.
5. pharmaceutical composition as described in claim 1, which is characterized in that the dosage form of described pharmaceutical composition is pharmaceutically to allow
Any dosage form.
6. pharmaceutical composition as claimed in claim 5, which is characterized in that the dosage form is selected from sublingual containing agent, transdermal patch, piece
Agent, granule, pulvis, pill, spray, patch, any one in film.
7. such as application of the pharmaceutical composition of any of claims 1-6 in the drug of preparation treatment of cancer pain.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910169425.8A CN109846882A (en) | 2019-03-06 | 2019-03-06 | A kind of pharmaceutical composition and its application for analgesic |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201910169425.8A CN109846882A (en) | 2019-03-06 | 2019-03-06 | A kind of pharmaceutical composition and its application for analgesic |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109846882A true CN109846882A (en) | 2019-06-07 |
Family
ID=66900003
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201910169425.8A Pending CN109846882A (en) | 2019-03-06 | 2019-03-06 | A kind of pharmaceutical composition and its application for analgesic |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109846882A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1355049A (en) * | 2000-11-30 | 2002-06-26 | 王泽时 | Analgesic and its preparing process |
| WO2015097059A1 (en) * | 2013-12-23 | 2015-07-02 | Hexal Ag | Pharmaceutical composition comprising buprenorphine |
-
2019
- 2019-03-06 CN CN201910169425.8A patent/CN109846882A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1355049A (en) * | 2000-11-30 | 2002-06-26 | 王泽时 | Analgesic and its preparing process |
| WO2015097059A1 (en) * | 2013-12-23 | 2015-07-02 | Hexal Ag | Pharmaceutical composition comprising buprenorphine |
Non-Patent Citations (2)
| Title |
|---|
| 孙晓萍 等: "冰片抗炎镇痛作用的实验研究", 《中药新药与临床药理》 * |
| 陈宁 等: "《镇痛药物使用手册》", 30 June 2015, 中国医药科技出版社 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Chang et al. | Gabapentin in acute postoperative pain management | |
| WO2014020155A1 (en) | Oral transmucosal adminstration forms of s-ketamine | |
| EP2574167B1 (en) | Liquid nasal spray containing low-dose naltrexone | |
| US6979689B2 (en) | Compositions and methods for treating upper respiratory congestion | |
| CA2661759A1 (en) | Buprenophine-wafer for drug substitution therapy | |
| CA2558896A1 (en) | Methods for the treatment of tinnitus induced by cochlear excitotoxicity | |
| Hooshang et al. | Complex regional pain syndrome. Reflex sympathetic dystrophy syndrome. Diagnosis and therapy-a review of 824 patients Abstract and summary | |
| AU2023251499A1 (en) | Combinations of opioids and N-acylethanolamines | |
| RU2006139819A (en) | APPLICATION OF SYMETICON FOR PATIENTS POSITIONED FOR CONSTIPATION | |
| CA2403994C (en) | Nasal administration of agents for the treatment of gastroparesis | |
| CA2646700A1 (en) | Terguride/proterguride for the treatment of chronic pain | |
| JP6196704B2 (en) | Medicament for the treatment of neuropathic diseases | |
| CN109846882A (en) | A kind of pharmaceutical composition and its application for analgesic | |
| CN1943575A (en) | Abuse potential low compound buprenorphin hydrochloride naloxone hydrochloride sublingual tablet | |
| US9889109B2 (en) | Pharmaceutical composition comprising benzyl alcohol for the treatment of migraines | |
| Gupta et al. | Diabetic neuropathy: Part 2 | |
| CA3066904A1 (en) | Bromhexine for the treatment of pain | |
| JP2009502828A (en) | A therapeutic combination comprising an NMDA receptor blocker and a narcotic analgesic | |
| WO2011000563A4 (en) | Eltoprazine for the treatment of weight disorders | |
| RU2004106611A (en) | COMPOSITIONS AND METHODS FOR PREVENTING ABUSE |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20190607 |